Skip to Main Content

REPRESENTATIVE EXPERIENCE

Andrew Gaffney

Acted as lead partner on the Australian Stock Exchange listing of Freightways Group Limited (ASX: FRW) as an ASX Foreign Exempt Listing on 12 September 2023.
Acted as lead partner for Symal Group Limited (ASX: SYL) on its successful IPO on the ASX, trading on the ASX under the ticker symbol 'SYL' in November 2024 with a market capitalisation of circa AU$500 million.
Advising as lead partner on IPO and ASX listings of Adherium Ltd; AirXpanders Inc (CDI listing); Allomak Ltd; Ascend Biopharma Ltd; CyGenics Ltd; Cordlife Group Limited (on Singapore SGX); DWS Advanced Business Solutions Ltd; DorsaVi Ltd; EvoGenix Ltd; Freightways Group Limited; Genetic Technologies Ltd (NASDAQ ADR listing); iCeutica Inc (CDI listing on ASX); Innovation Beverage Group Ltd (NASDAQ primary listing); Mesoblast Ltd; Micro-X Ltd; Money3 Ltd; Octagonal Resources Ltd; Osprey Medical Inc (CDI listing); Paradigm BioPharmaceuticals Ltd; Patrys Ltd; PayGroup Ltd; Prime Financial Group Ltd; Relevare Ltd; SelfWealth Ltd; Sienna Cancer Diagnostics Ltd; Simavita Ltd (dual TSX-V and ASX listing); Symal Group Limited; TSV Holdings Ltd; Visioneering Technologies Inc (CDI listing); Wattle Health Australia Ltd; and Zucero Therapeutics Ltd.
Advised Melbourne Victory Limited in its private equity investment by the US private equity group 777 Partners MV LLC and subsequent private equity investment by the UK investment group led by Mr Anthony Bloom.
Advised Actinogen Medical Limited on its non-renounceable entitlement offer with cornerstone commitment / partial underwriting. The structure of the raising with cornerstone commitments (rather than an underwriting) allowed wider participation in shortfall commitments by exempt investors under s708 of the Corporations Act. Being able to announce those commitments after trading halt showed investor confidence or validation in the NRRI offer in conjunction with admission of an additional class of listed security for ACW.
Advised Oncosil Medical Limited on its institutional placement and pro-rata non-renounceable entitlement offer to existing shareholders to raise in aggregate AU$10 million. The offers involved the establishment of an additional class of listed security for the client (listed options ASX code OSLO) – which augmented the attractiveness of the offers. Structured as a placement (to give new institutional investors a firm commitment) and then a follow-on NRRI offer to existing shareholders (gave existing shareholders an opportunity to participate at the same pricing as the placement).
Return to top of page

Email Disclaimer

We welcome your email, but please understand that if you are not already a client of K&L Gates LLP, we cannot represent you until we confirm that doing so would not create a conflict of interest and is otherwise consistent with the policies of our firm. Accordingly, please do not include any confidential information until we verify that the firm is in a position to represent you and our engagement is confirmed in a letter. Prior to that time, there is no assurance that information you send us will be maintained as confidential. Thank you for your consideration.

Accept Cancel